Kuros Biosciences AG (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kuros Biosciences AG (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH81908D
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company's lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG (KURN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Kuros Biosurgery Raises Additional USD5 Million Financing 12

Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13

Merger 14

Cytos Biotech Merges with Kuros Biosurgery 14

Licensing Agreements 15

Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15

Cytos Biotechnology Enters into License Agreement with Novartis 16

Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17

Equity Offering 18

Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18

Kuros Biosciences Raises Funds through Rights Offering of Shares 19

Kuros Biosciences Raises Funds through Public Offering of Shares 20

Cytos Biotechnology Completes Rights Offering Of Shares For USD 26.7 Million 21

Cytos Biotechnology Completes Private Placement Of Shares For USD 26 Million 22

Cytos Biotechnology Completes Rights Offering Of Shares For USD 3.5 Million 24

Debt Offering 26

Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For USD 14.5 Million 26

Kuros Biosciences AG-Key Competitors 28

Kuros Biosciences AG-Key Employees 29

Kuros Biosciences AG-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Sep 05, 2018: Kuros Biosciences announces results for first half 2018 31

Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results 32

Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 33

Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 34

Corporate Communications 36

Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer 36

May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM 37

Dec 14, 2017: Kuros Biosciences Announces Management Succession 38

Nov 28, 2017: Kuros Biosciences' Chief Medical Officer to Retire 39

Nov 16, 2017: Kuros announces management changes 40

Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 41

Apr 13, 2017: Kuros announces CEO succession 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43

List of Figures

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kuros Biosciences AG, Deals By Therapy Area, 2012 to YTD 2018 9

Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kuros Biosurgery Raises Additional USD5 Million Financing 12

Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13

Cytos Biotech Merges with Kuros Biosurgery 14

Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15

Cytos Biotechnology Enters into License Agreement with Novartis 16

Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17

Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18

Kuros Biosciences Raises Funds through Rights Offering of Shares 19

Kuros Biosciences Raises Funds through Public Offering of Shares 20

Cytos Biotechnology Completes Rights Offering Of Shares For USD 26.7 Million 21

Cytos Biotechnology Completes Private Placement Of Shares For USD 26 Million 22

Cytos Biotechnology Completes Rights Offering Of Shares For USD 3.5 Million 24

Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For USD 14.5 Million 26

Kuros Biosciences AG, Key Competitors 28

Kuros Biosciences AG, Key Employees 29

Kuros Biosciences AG, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Kuros Biosciences AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17948
Site License
USD 500 INR 35895
Corporate User License
USD 750 INR 53843

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com